title: Sepsis syndrome and associated sequelae in patients at high risk for gram-negative sepsis.
abstract: We conducted a prospective surveillance study of 80 hospitals across the United States to determine the incidence of sepsis syndrome and its associated sequelae in hospitalized patients over age 18 years who were administered antibiotics for suspected or documented gram-negative infection. A sample of 1754 hospitalized patients were followed from onset of antimicrobial therapy to discharge or death. Mortality rates (MR) varied depending on the suspected source of sepsis syndrome. For patients in whom the syndrome was associated with community-acquired urinary tract infections, mortality was 20% (relative risk [RR] = 0.51, p < 0.05), for those with trauma 20.6% (RR = 0.51, p < 0.05), and patients with nosocomial respiratory tract infections 57.1% (RR = 1.66, p < 0.05). More than two complications occurred in 65.2% of patients under age 60 years (MR 31%), 40.8% of those age 60-80 (MR 42%), and 35.6% of patients older than 80 years (MR 33.3%, p > 0.05). Various patient populations had significant differences in both the incidence of the syndrome and its complications, and consequent mortality. Perhaps morbidity as well as mortality should be used as outcomes when testing the efficacy of innovative therapies for sepsis.
authors.affiliation: Center for Pharmacoepidemiology Research, State University of New York at Buffalo 14260, USA.
authors.forename: K
authors.initials: K
authors.lastname: Conboy
authors.forename: L S
authors.initials: LS
authors.lastname: Welage
authors.forename: C A
authors.initials: CA
authors.lastname: Walawander
authors.forename: L C
authors.initials: LC
authors.lastname: Duffy
authors.forename: R C
authors.initials: RC
authors.lastname: Welliver
authors.forename: M A
authors.initials: MA
authors.lastname: Zielezny
authors.forename: J T
authors.initials: JT
authors.lastname: DiPiro
authors.forename: M A
authors.initials: MA
authors.lastname: Raebel
authors.forename: T H
authors.initials: TH
authors.lastname: Grasela
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000453:epidemiology; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000453:epidemiology; D003428:Cross Infection / Q000188:drug therapy / Q000453:epidemiology; D005260:Female; D016905:Gram-Negative Bacterial Infections / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology*; D006760:Hospitalization; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D011159:Population Surveillance; D011446:Prospective Studies; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000453:epidemiology; D012307:Risk Factors; D018746:Systemic Inflammatory Response Syndrome / Q000150:complications / Q000453:epidemiology*; D014481:United States / Q000453:epidemiology; D014552:Urinary Tract Infections / Q000150:complications / Q000453:epidemiology
chemical_list: D000900:Anti-Bacterial Agents